The role of general practitioners in managing and treating hepatitis C

Medical Journal of Australia

Volumn 191, Issue 10, 2009, Pages 523-524

  Hellard, Margaret E ^a   Wang, Yung Hsuan J ^a  

^a BURNET INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN; RNA;

EDITORIAL; GENERAL PRACTITIONER; HEPATITIS C; HUMAN; MEDICAL EDUCATION; MEDICAL PRACTICE; MEDICAL SPECIALIST; PATIENT CARE; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE; AUSTRALIA; GENERAL PRACTICE; ORGANIZATION AND MANAGEMENT; PHYSICIAN ATTITUDE;

AUSTRALIA; FAMILY PRACTICE; HEPATITIS C; HUMANS; PHYSICIAN'S ROLE; PHYSICIANS, FAMILY;

EID: 77449089053     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2009.tb03300.x     Document Type: Editorial

References (13)

1. Ministerial Advisory Committee on AIDS, Sexual Health and Hepatitis: Hepatitis C Sub-Committee. Hepatitis C Virus Projections Working Group: estimates and projections of the hepatitis C virus epidemic in Australia 2006. Sydney: National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 2006.
2. Kim AI, Saab S. Treatment of hepatitis C. Am J Med 2005; 118: 808-815.
3. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313. (Pubitemid 34465173)
4. Abbott T. Australians with hepatitis C gain easier access to treatments [press release]. 20 Feb 2006. www.health.gov.au/internet/ministers/publishing. nsf/Content/6E130AAD737A22FFCA25711B000E9BB6/$File/abb019.pdf (accessed Jul 2009).
5. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2009. Sydney: NCHECR, University of New South Wales, 2009.
6. Hallinan R, Byrne A, Dore GJ. Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction. Drug Alcohol Rev 2007; 26: 437-443.
7. Dev A, Sievert W. A survey of Australian general practice management of hepatitis C-infected patients from non-English-speaking backgrounds. J Gastroenterol Hepatol 2002; 17: 295-300. (Pubitemid 34534102)
8. Gupta L, Shah S, Ward JE. Educational and health service needs of Australian general practitioners in managing hepatitis C. J Gastroenterol Hepatol 2006; 21: 694-699.
9. Wang J, Guy R, Hellard M. The Victorian hepatitis C education program for GPs: an evaluation. Aust Fam Physician 2009; 38: 749-752.
10. Gifford SM, O'Brien ML, Bammer G, et al. Australian women's experiences of living with hepatitis C virus: results from a cross-sectional survey. J Gastroenterol Hepatol 2003; 18: 841-850. (Pubitemid 36936578)
11. Gifford SM, O'Brien ML, Smith A, et al. Australian men's experiences of living with hepatitis C virus: results from a cross-sectional survey. J Gastroenterol Hepatol 2005; 20: 79-86. (Pubitemid 40143638)
12. van der Poel CL, Cuypers HT, Reesink HW. Hepatitis C virus six years on. Lancet 1994; 344: 1475-1479.
13. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965. (Pubitemid 32913521)